SAPIEN M3 Transcatheter Mitral Valve Replacement System
Edwards Lifesciences, LLC · Decision date Feb 19, 2026
What did the FDA approve?
FDA records P250019/S001 as a supplement to PMA P250019, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Feb 19, 2026.
FDA approval order statement
Approval of the protocols for the post-approval studies, "Continued Follow-up of ENCIRCLE Premarket Cohort" and "Registry-Based Real-World Use Surveillance", submitted to comply with the conditions of approval outlined in the approval order for P250019.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Feb 19, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P250019/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPU
- Decision code
- APPR
- Decision date
- Feb 19, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, mitral valve, percutaneously delivered.
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPU
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250019. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250019 · Original PMA
SAPIEN M3 Transcatheter Mitral Valve Replacement System
P250019/S001 received
Application receipt date recorded by FDA.
P250019/S001 · FDA decision
Normal 180 Day Track No User Fee
P250019/S002 · Related supplement
Edwards SAPIEN M3 Transcatheter Heart Valve (sizes 20mm, 23mm, 26mm, 29mm)
P250019/S003 · Related supplement
SAPIEN M3 Transcatheter Mitral Valve Replacement System
P250019/S005 · Related supplement
SAPIEN M3 Transcatheter Heart Valve (9880TFX29M)
P250019/S006 · Related supplement
Edwards SAPIEN M3 Dock (988DDS); Edwards 23F Guide Sheath (9880GS); Edwards SAPIEN M3 Crimper (9880CR); Edwards Commande
Timeline entries are records held by MedtechLedger for P250019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA approval | Dec 22, 2025 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Mar 11, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Apr 16, 2026 | FDA | |
SAPIEN M3 Transcatheter Heart Valve (9880TFX29M)P250019/S005 | Edwards Lifesciences, LLC | PMA supplement | Jul 28, 2026 | FDA |
| Edwards Lifesciences, LLC | PMA supplement | Jul 29, 2026 | FDA |
Explore the linked device profile
Other records with product code NPU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Tendyne Transcatheter Mitral Valve SystemP240042/S004 | ABBOTT MEDICAL | PMA supplement | Aug 31, 2026 | FDA |
Tendyne Transcatheter Mitral Valve SystemP240042/S003 | ABBOTT MEDICAL | PMA supplement | Aug 7, 2026 | FDA |
Tendyne Transcatheter Mitral Valve SystemP240042/S002 | ABBOTT MEDICAL | PMA supplement | Oct 4, 2025 | FDA |
Tendyne Transcatheter Mitral ValveP240042/S001 | ABBOTT MEDICAL | PMA supplement | Jul 29, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Edwards Lifesciences, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- One Edwards Way, Irvine, CA, 92614
Sources and methodology
- Original FDA record: P250019/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
